Global LAMEA Oncology/Anti-cancer drugs Market Insights, Research, Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 113

Report ID: 12036

The global LAMEA Oncology/Anti-cancer drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the LAMEA Oncology/Anti-cancer drugs market based on company, product type, end user and key regions.

This report studies the global market size of LAMEA Oncology/Anti-cancer drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of LAMEA Oncology/Anti-cancer drugs in these regions.
This research report categorizes the global LAMEA Oncology/Anti-cancer drugs market by top players/brands, region, type and end user. This report also studies the global LAMEA Oncology/Anti-cancer drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Novartis
Celgene
Amgen
Johnson & Johnson
GlaxoSmithKline
Eli lilly & Co
Pfizer
Merck & Co.
Sanofi

Market size by Product
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Others
Market size by End User
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global LAMEA Oncology/Anti-cancer drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of LAMEA Oncology/Anti-cancer drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global LAMEA Oncology/Anti-cancer drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of LAMEA Oncology/Anti-cancer drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of LAMEA Oncology/Anti-cancer drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of LAMEA Oncology/Anti-cancer drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 LAMEA Oncology/Anti-cancer drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global LAMEA Oncology/Anti-cancer drugs Market Size Growth Rate by Product
1.4.2 Blood Cancer
1.4.3 Breast Cancer
1.4.4 Gastrointestinal Cancer
1.4.5 Prostate Cancer
1.4.6 Others
1.5 Market by End User
1.5.1 Global LAMEA Oncology/Anti-cancer drugs Market Size Growth Rate by End User
1.5.2 Chemotherapy
1.5.3 Targeted Therapy
1.5.4 Immunotherapy (Biologic Therapy)
1.5.5 Hormonal Therapy
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global LAMEA Oncology/Anti-cancer drugs Market Size
2.1.1 Global LAMEA Oncology/Anti-cancer drugs Revenue 2014-2025
2.1.2 Global LAMEA Oncology/Anti-cancer drugs Sales 2014-2025
2.2 LAMEA Oncology/Anti-cancer drugs Growth Rate by Regions
2.2.1 Global LAMEA Oncology/Anti-cancer drugs Sales by Regions
2.2.2 Global LAMEA Oncology/Anti-cancer drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 LAMEA Oncology/Anti-cancer drugs Sales by Manufacturers
3.1.1 LAMEA Oncology/Anti-cancer drugs Sales by Manufacturers
3.1.2 LAMEA Oncology/Anti-cancer drugs Sales Market Share by Manufacturers
3.1.3 Global LAMEA Oncology/Anti-cancer drugs Market Concentration Ratio (CR5 and HHI)
3.2 LAMEA Oncology/Anti-cancer drugs Revenue by Manufacturers
3.2.1 LAMEA Oncology/Anti-cancer drugs Revenue by Manufacturers (2014-2019)
3.2.2 LAMEA Oncology/Anti-cancer drugs Revenue Share by Manufacturers (2014-2019)
3.3 LAMEA Oncology/Anti-cancer drugs Price by Manufacturers
3.4 LAMEA Oncology/Anti-cancer drugs Manufacturing Base Distribution, Product Types
3.4.1 LAMEA Oncology/Anti-cancer drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers LAMEA Oncology/Anti-cancer drugs Product Type
3.4.3 Date of International Manufacturers Enter into LAMEA Oncology/Anti-cancer drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global LAMEA Oncology/Anti-cancer drugs Sales by Product
4.2 Global LAMEA Oncology/Anti-cancer drugs Revenue by Product
4.3 LAMEA Oncology/Anti-cancer drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global LAMEA Oncology/Anti-cancer drugs Breakdown Data by End User

6 North America
6.1 North America LAMEA Oncology/Anti-cancer drugs by Countries
6.1.1 North America LAMEA Oncology/Anti-cancer drugs Sales by Countries
6.1.2 North America LAMEA Oncology/Anti-cancer drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America LAMEA Oncology/Anti-cancer drugs by Product
6.3 North America LAMEA Oncology/Anti-cancer drugs by End User

7 Europe
7.1 Europe LAMEA Oncology/Anti-cancer drugs by Countries
7.1.1 Europe LAMEA Oncology/Anti-cancer drugs Sales by Countries
7.1.2 Europe LAMEA Oncology/Anti-cancer drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe LAMEA Oncology/Anti-cancer drugs by Product
7.3 Europe LAMEA Oncology/Anti-cancer drugs by End User

8 Asia Pacific
8.1 Asia Pacific LAMEA Oncology/Anti-cancer drugs by Countries
8.1.1 Asia Pacific LAMEA Oncology/Anti-cancer drugs Sales by Countries
8.1.2 Asia Pacific LAMEA Oncology/Anti-cancer drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific LAMEA Oncology/Anti-cancer drugs by Product
8.3 Asia Pacific LAMEA Oncology/Anti-cancer drugs by End User

9 Central & South America
9.1 Central & South America LAMEA Oncology/Anti-cancer drugs by Countries
9.1.1 Central & South America LAMEA Oncology/Anti-cancer drugs Sales by Countries
9.1.2 Central & South America LAMEA Oncology/Anti-cancer drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America LAMEA Oncology/Anti-cancer drugs by Product
9.3 Central & South America LAMEA Oncology/Anti-cancer drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa LAMEA Oncology/Anti-cancer drugs by Countries
10.1.1 Middle East and Africa LAMEA Oncology/Anti-cancer drugs Sales by Countries
10.1.2 Middle East and Africa LAMEA Oncology/Anti-cancer drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa LAMEA Oncology/Anti-cancer drugs by Product
10.3 Middle East and Africa LAMEA Oncology/Anti-cancer drugs by End User

11 Company Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Company Business Overview
11.1.3 Roche LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Roche LAMEA Oncology/Anti-cancer drugs Products Offered
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Company Business Overview
11.2.3 Novartis LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Novartis LAMEA Oncology/Anti-cancer drugs Products Offered
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Details
11.3.2 Company Business Overview
11.3.3 Celgene LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Celgene LAMEA Oncology/Anti-cancer drugs Products Offered
11.3.5 Celgene Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Company Business Overview
11.4.3 Amgen LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Amgen LAMEA Oncology/Anti-cancer drugs Products Offered
11.4.5 Amgen Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Company Business Overview
11.5.3 Johnson & Johnson LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Johnson & Johnson LAMEA Oncology/Anti-cancer drugs Products Offered
11.5.5 Johnson & Johnson Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 Company Business Overview
11.6.3 GlaxoSmithKline LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 GlaxoSmithKline LAMEA Oncology/Anti-cancer drugs Products Offered
11.6.5 GlaxoSmithKline Recent Development
11.7 Eli lilly & Co
11.7.1 Eli lilly & Co Company Details
11.7.2 Company Business Overview
11.7.3 Eli lilly & Co LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Eli lilly & Co LAMEA Oncology/Anti-cancer drugs Products Offered
11.7.5 Eli lilly & Co Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Company Business Overview
11.8.3 Pfizer LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Pfizer LAMEA Oncology/Anti-cancer drugs Products Offered
11.8.5 Pfizer Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Company Business Overview
11.9.3 Merck & Co. LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Merck & Co. LAMEA Oncology/Anti-cancer drugs Products Offered
11.9.5 Merck & Co. Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Company Business Overview
11.10.3 Sanofi LAMEA Oncology/Anti-cancer drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Sanofi LAMEA Oncology/Anti-cancer drugs Products Offered
11.10.5 Sanofi Recent Development

12 Future Forecast
12.1 LAMEA Oncology/Anti-cancer drugs Market Forecast by Regions
12.1.1 Global LAMEA Oncology/Anti-cancer drugs Sales Forecast by Regions 2019-2025
12.1.2 Global LAMEA Oncology/Anti-cancer drugs Revenue Forecast by Regions 2019-2025
12.2 LAMEA Oncology/Anti-cancer drugs Market Forecast by Product
12.2.1 Global LAMEA Oncology/Anti-cancer drugs Sales Forecast by Product 2019-2025
12.2.2 Global LAMEA Oncology/Anti-cancer drugs Revenue Forecast by Product 2019-2025
12.3 LAMEA Oncology/Anti-cancer drugs Market Forecast by End User
12.4 North America LAMEA Oncology/Anti-cancer drugs Forecast
12.5 Europe LAMEA Oncology/Anti-cancer drugs Forecast
12.6 Asia Pacific LAMEA Oncology/Anti-cancer drugs Forecast
12.7 Central & South America LAMEA Oncology/Anti-cancer drugs Forecast
12.8 Middle East and Africa LAMEA Oncology/Anti-cancer drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 LAMEA Oncology/Anti-cancer drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer